FAQ: Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.

RhAPPcast

Join Heather Mambretti, PA-C, a rheumatology specialist in Houston, Texas, as she explores the critical role of IL-23 in autoimmune disease pathogenesis and how IL-23 inhibitors have revolutionized treatment strategies for psoriasis, psoriatic arthritis (PsA), and inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.

IL-23 is a key cytokine produced by dendritic and macrophage cells, driving TH17 cell differentiation and fueling chronic inflammation. In psoriasis and PsA, dysregulated IL-23 signaling promotes TH17 proliferation, leading to increased IL-17A and IL-17F production—major contributors to inflammation in skin and joints. In IBD, IL-23 plays a similar role, disrupting intestinal barrier integrity and perpetuating chronic inflammation in conditions like Crohn’s disease and ulcerative colitis.

Targeting IL-23 with selective inhibitors has transformed the treatment landscape, offering a precise approach that reduces TH17-driven inflammation while preserving broader immune function. Clinical evidence, including a 2021 Rheumatology Journal publication, underscores IL-23’s pivotal role as the key link between skin, gut, and joint inflammation, making IL-23 inhibition an essential strategy in managing these autoimmune conditions.

IL-23 inhibitors provide effective, targeted therapy, reducing systemic inflammation, improving symptoms, and enhancing long-term patient outcomes across multiple inflammatory diseases.

Want to learn more? Visit the RhAPP website or explore additional educational resources on the RhAPP ACE App.

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.

Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada